Bölüm notları
What happens when a MedTech company successfully gets through FDA?
That is often when the real work begins.
In this episode of Bluestock Talk, Allison is joined by reimbursement expert Mark Domyahn, Partner at JD Lymon Group (and Bluestocking Health Advisory Board member), to explore one of the most important (and frequently misunderstood) aspects of MedTech commercialization: getting paid.
As Mark explains, regulatory approval is only one piece of the puzzle. Hospitals, physicians, payers, and investors all evaluate new technologies differently, and increasingly, investors want to…

